Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2016-08-17 Regulatory Filings
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Adaptimmune Therapeutics plc to the SEC's Division of Corporation Finance regarding comments on the company's Form 20-F transition report and a Form 8-K filing. It discusses accounting policies, financial statement notes, and management's analysis of financial disclosures, including research and development expenses and revenue recognition under a collaboration agreement. The letter references specific SEC comment letters and accounting standards (ASC 730, ASC 605), and it addresses the company's financial reporting and disclosures. The document is not the actual Form 20-F or 8-K report but a correspondence responding to SEC comments on those filings. It contains detailed financial and accounting discussion but is primarily a regulatory correspondence letter rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and compliance documents that do not fit other specific categories.
2016-08-17 English
Regulatory Filings 2016
Regulatory Filings
2016-08-16 English
4
Director's Dealing
2016-08-13 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-12 English
FORM 4 SUBMISSION
Director's Dealing
2016-08-12 English
4
Director's Dealing
2016-08-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.